Aligos Therapeutics, Inc. (ALGS) Financials

ALGS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 66.3 million 34.4 million
March 31, 2026 64.6 million 32.8 million
Dec. 31, 2025 89.6 million 36.0 million
Sept. 30, 2025 109.8 million 37.9 million

ALGS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -25.0 million 1.4 million
March 31, 2026 -23.2 million 1.3 million
Dec. 31, 2025 -21.8 million 1.5 million
Sept. 30, 2025 -24.5 million 1.5 million

ALGS Net Income

No data available :(

ALGS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 30.4 million - 3.5 million
March 31, 2026 55.1 million - 659000
Dec. 31, 2025 78.0 million - 1.5 million
Sept. 30, 2025 99.1 million - 6.1 million

ALGS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 10.4 million
March 31, 2026 10.4 million
Dec. 31, 2025 10.4 million
Sept. 30, 2025 10.4 million

ALGS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 1000 24.1 million 5.6 million -
March 31, 2026 69000 23.4 million 6.4 million -
Dec. 31, 2025 92000 17.0 million 4.7 million -
Sept. 30, 2025 193000 23.9 million 5.2 million -

ALGS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 27.8 million -
March 31, 2026 2.8 million -
Dec. 31, 2025 169000 257000
Sept. 30, 2025 741000 -

ALGS

Price: $6.76

52 week price:
3.98
13.69

Earnings Per Share: -7.43 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 78576

Market Capitalization: 43.7 million

Links: